Pages that link to "Q2378309"
Jump to navigation
Jump to search
The following pages link to cancer vaccine (Q2378309):
Displaying 50 items.
- Avicine (Q4655047) (← links)
- CimaVax-EGF (Q5120048) (← links)
- Gp100:209-217(210M) (Q5590513) (← links)
- Neuvenge (Q7003154) (← links)
- TroVax (Q7844782) (← links)
- Category:Cancer vaccines (Q10811244) (← links)
- Hasumi vaccine (Q11326347) (← links)
- Oncolytic viruses as therapeutic cancer vaccines (Q21245758) (← links)
- RNA vaccines in cancer treatment (Q21296852) (← links)
- Improved Endpoints for Cancer Immunotherapy Trials (Q24603112) (← links)
- Challenges to the development of antigen-specific breast cancer vaccines (Q24793404) (← links)
- Update on HER-2 as a target for cancer therapy: HER2/neu peptides as tumour vaccines for T cell recognition (Q24801995) (← links)
- Cancer vaccines: the next generation of tools to monitor the anticancer immune response (Q24814450) (← links)
- Dendritic-Tumor Fusion Cell-Based Cancer Vaccines (Q26744827) (← links)
- Cancer immunotherapy: the beginning of the end of cancer? (Q26752277) (← links)
- Vaccine adjuvants as potential cancer immunotherapeutics (Q26752522) (← links)
- Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination (Q26769044) (← links)
- Towards Targeted Delivery Systems: Ligand Conjugation Strategies for mRNA Nanoparticle Tumor Vaccines (Q26773073) (← links)
- RNA-Based Vaccines in Cancer Immunotherapy (Q26776028) (← links)
- Peptide-Based Treatment: A Promising Cancer Therapy (Q26777032) (← links)
- Cancer anti-angiogenesis vaccines: Is the tumor vasculature antigenically unique? (Q26778150) (← links)
- Adjuvant for vaccine immunotherapy of cancer--focusing on Toll-like receptor 2 and 3 agonists for safely enhancing antitumor immunity (Q26782131) (← links)
- Cancer vaccines: state of the art of the computational modeling approaches (Q26825044) (← links)
- Current vaccine trials in glioblastoma: a review (Q26828965) (← links)
- Lung cancer: a classic example of tumor escape and progression while providing opportunities for immunological intervention (Q26850218) (← links)
- From bench to bedside: immunotherapy for prostate cancer (Q26864390) (← links)
- Anti-cancer vaccines - a one-hit wonder? (Q26995164) (← links)
- Therapy decisions for the symptomatic patient with metastatic castration-resistant prostate cancer (Q27002342) (← links)
- Understanding dendritic cells and their role in cutaneous carcinoma and cancer immunotherapy (Q27004702) (← links)
- Cancer vaccines: are we there yet? (Q27012732) (← links)
- Pros and Cons of Antigen-Presenting Cell Targeted Tumor Vaccines (Q27013679) (← links)
- Translation of genomics-guided RNA-based personalised cancer vaccines: towards the bedside (Q27015695) (← links)
- Peptide intra-tumor injection for cancer immunotherapy: enhancement of tumor cell antigenicity is a novel and attractive strategy (Q27020970) (← links)
- Cancer vaccines (Q27024438) (← links)
- Optimal MHC-II-restricted tumor antigen presentation to CD4+ T helper cells: the key issue for development of anti-tumor vaccines (Q27030560) (← links)
- The application of the fibroblast activation protein α-targeted immunotherapy strategy (Q28073437) (← links)
- DNA vaccine for cancer immunotherapy (Q28080919) (← links)
- Design of universal cancer vaccines using natural tumor vessel-specific antigens (SANTAVAC) (Q28087470) (← links)
- Provenge (Q29006380) (← links)
- Clinical Outcomes of Specific Immunotherapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis. (Q30235405) (← links)
- Modeling flow cytometry data for cancer vaccine immune monitoring (Q33610175) (← links)
- Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications (Q33621393) (← links)
- Ovarian cancer immunotherapy: opportunities, progresses and challenges (Q33702218) (← links)
- Vaccines against human carcinomas: strategies to improve antitumor immune responses (Q33734281) (← links)
- DNA vaccines: developing new strategies against cancer (Q33756622) (← links)
- Microenvironment, oncoantigens, and antitumor vaccination: lessons learned from BALB-neuT mice (Q33786788) (← links)
- New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016 (Q33814908) (← links)
- The Therapeutic Benefit of Bacterial Membrane Vesicles (Q33839021) (← links)
- Adjuvant therapy for locally advanced renal cell cancer: A systematic review with meta-analysis (Q33858807) (← links)
- Dendritic Cell Based Tumor Vaccination in Prostate and Renal Cell Cancer: A Systematic Review and Meta-Analysis (Q33886261) (← links)